Single-cell methods in myeloproliferative neoplasms: old questions, new technologies
Blood · 2023
DOI: 10.1182/blood.2021014668 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Blood, 2023. Verfasst von Jennifer Mary O'Sullivan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Council Molecular Haematology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, University of Oxford, Oxfor…. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Bone Marrow Neoplasms, Hematologic Neoplasms, Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medical Research Council, Cancer Research UK.
Abstract (Originalsprache)
Myeloproliferative neoplasms (MPN) are a group of clonal stem cell–derived hematopoietic malignancies driven by aberrant Janus kinase-signal transducer and activator of transcription proteins (JAK/STAT) signaling. Although these are genetically simple diseases, MPNs are phenotypically heterogeneous, reflecting underlying intratumoral heterogeneity driven by the interplay of genetic and nongenetic factors. Their evolution is determined by factors that enable certain cellular subsets to outcompete others. Therefore, techniques that resolve cellular heterogeneity at the single-cell level are ideally placed to provide new insights into MPN biology. With these insights comes the potential to uncover new approaches to predict the clinical course and treat these cancers, ultimately improving outcomes for patients. MPNs present a particularly tractable model of cancer evolution, because most patients present in an early disease phase and only a small proportion progress to aggressive disease. Therefore, it is not surprising that many groundbreaking technological advances in single-cell omics have been pioneered by their application in MPNs. In this review article, we explore how single-cell approaches have provided transformative insights into MPN disease biology, which are broadly applicable across human cancers, and discuss how these studies might be swiftly translated into clinical pathways and may eventually underpin precision medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical Research Council Molecular Haematology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
- NIHR Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.
ORCID-Profile: Adam J Mead, Bethan Psaila
Förderung
- Medical Research Council
- Cancer Research UK
Zitieren
APA
O'Sullivan, J. M., Mead, A. J., & Psaila, B. (2023). Single-cell methods in myeloproliferative neoplasms: old questions, new technologies. Blood. https://doi.org/10.1182/blood.2021014668
Vancouver
O'Sullivan JM, Mead AJ, Psaila B. Single-cell methods in myeloproliferative neoplasms: old questions, new technologies. Blood. 2023. doi:10.1182/blood.2021014668
BibTeX
@article{OSullivan2023,
author = {O'Sullivan, Jennifer Mary and Mead, Adam J and Psaila, Bethan},
title = {Single-cell methods in myeloproliferative neoplasms: old questions, new technologies},
journal = {Blood},
year = {2023},
doi = {10.1182/blood.2021014668}
}
EUVIMED